Akademik Veri Yönetim Sistemi
Polyhedron, cilt.289, 2026 (SCI-Expanded, Scopus)
Ruthenium(II) N-heterocyclic carbene (NHC) complexes are widely studied due to their promising anticancer activities and catalytic properties. Herein, five novel Ru(II)-NHC complexes were synthesized and characterized using various methods such as elemental analysis, FT-IR, 1H NMR, and 13C NMR techniques. The catalytic activities of the complexes in the transfer hydrogenation reaction were tested and the results showed that they were effective catalysts in this reaction. Moreover, in vitro anticancer activities were investigated based on three cell lines, including two cancer cell lines (HCT 116, A549) and one normal cell line (L-929). All complexes exhibited significant cytotoxic activity at all tested concentrations against the cancer cell lines. The IC50 values showed that the complexes exhibited superior activity as compared to cisplatin. The anticancer activities of Ru-NHC complexes vary depending on the substituent group of the complex and the type of cell line. However, complex 2a showed better anticancer activity (IC50 = 7.66 ± 2.83 μM) than that exhibited by cisplatin (IC50 = 121.78 ± 9.35 μM) against the HCT116 cell line. Similarly, complex 2a (IC50 = 42.47 ± 3.10 μM) demonstrated significant activity compared to cisplatin (IC50 = 181.23 ± 5.44 μM) against the A549 cell line. In contrast, complexes exhibited low cytotoxic activity against L-929 cells (33.65–95.18 μM). Moreover, cell imaging of complexes 2a, 2c, and 2d was examined against cell lines using fluorescence microscopy. Based on our results, complex 2a is an intriguing candidate for future investigations as a potential anticancer drug for the treatment of different cancers.